Post marketing studies and clinical trials for artesunate for injection.
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH21C0105
- Awardee
-
Amivas US LLC UEI M4JCSH678BQ6
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $4,542,593
Award facts
- Opportunity
-
- W81XWH21R0043 Solicitation number
- Contract value 100% obligated
- $4,542,593.05 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- AJ13 General Science & Technology R&D Svcs; General Science & Technology; Experimental Development
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Fixed Price Level of Effort
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $613,277 | |
| Other Administrative Action | $0 | |
| Original award | $3,929,316 |
About this award
Amivas US LLC has been awarded a $4.5 million definitive contract from the Defense Health Agency to conduct post marketing studies and clinical trials for Artesunate for Injection. As the exclusive manufacturer and marketer of this branded anti-malarial drug in the U.S. through 2026, Amivas will leverage its expertise in pharmaceutical product development, manufacturing and commercialization to deliver the requested clinical research services. Performance will take place at Fort Detrick in Maryland through August 2023. No set-aside designation was applied to this award to Amivas, which has previously supplied Artesunate for Injection to the DHA and holds Federal Supply Schedule contracts with the Department of Veterans Affairs and DHA to provide pharmaceuticals and related products.
Quick answers
Who was awarded contract W81XWH21C0105?
W81XWH21C0105 was awarded to Amivas US LLC by Defense Health Agency (Department of Defense) on August 27, 2021.
How much is contract W81XWH21C0105 worth?
The government has obligated $4,542,593 on W81XWH21C0105.
Was contract W81XWH21C0105 competed?
The extent of competition for W81XWH21C0105 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award